International, Multi-center Post Authorization Surveillance Study on the Use of Nebido to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido).

Trial Profile

International, Multi-center Post Authorization Surveillance Study on the Use of Nebido to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido).

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions
  • Acronyms IPASS Nebido
  • Sponsors Bayer; Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2011 Final results presented at the 26th Congress of the European Association of Urology.
    • 23 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top